Tomosynthesis carries a great promise in improving cancer detection and reducing the number of false positives. As yet its drawbacks are: higher and longer radiation exposure, longer compression time and therefore longer lasting pain and longer interpretation time. However, is there a role for tomosynthesis in screening?
This conference topic will address many elements. Is tomosynthesis the better screening mammogram? Does digital breast tomosynthesis (DBT) reduce interval cancers? What are the technical hurdles (compatibility, data volumes) to use DBT in screening? How to compare with previous mammograms? Is DBT screening cost effective? What are the views of screening programs and the European Commission?
Is there a future for “Risk based screening”? There is a variable breast cancer risk in the population. You can think of familial risk factors, genetic risk factors, breast density but also age. Often some of these subgroups are excluded from screening or need additional imaging. Is it possible for a screening program to offer personalized services for high risk groups and how can we calculate the risk level?
- Breast Cancer screening programs and policies
- Is Tomosynthesis Ready for Prime Time?
- Risk based screening
- Hot topics in breast screening
Chairs: F. Cardoso, PT – C. de Wolf, CH – J. Geraghty, IE
Consult the ESO website for further info.